Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 25

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Neoplasm malignant

Recruiting

A study to test the safety and effects of TLN-372 alone and with other cancer drugs in patients with advanced solid tumors with KRAS gene changes

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Treeline Biosciences Inc.

Squamous cell carcinoma of head and neck

Recruiting

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ivonescimab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Endometrial cancer

Recruiting

A Study of Inavolisib for Patients with Advanced Endometrial Cancer Who Have PIK3CA Gene Mutations

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Acute myeloid leukaemia

Recruiting

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Quizartinib Dihydrochloride
  • Sponsor:Fundacion PETHEMA

Bladder cancer+2

Recruiting

A Study of Autologous Urothelial Cell Treatment with Bioprinter During Bladder Reconstruction Surgery in Patients with Muscle-Invasive Bladder Cancer

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:AUROCELL-TX
  • Sponsor:Phosprint S.A.

Acute myeloid leukaemia

Recruiting

A Study Comparing Two Treatment Schedules of Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Suitable for Intensive Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Azacitidine
  • Sponsor:Institut Gustave Roussy

Hepatocellular carcinoma+2

Recruiting

Long-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RP2
  • Sponsor:Replimune Group Inc.

Ovarian cancer

Recruiting

A Study of Mirvetuximab Soravtansine, Carboplatin, and Bevacizumab in Adults with Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cervix carcinoma

Recruiting

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Ovarian cancer

Recruiting

A Study of INCB123667 in Patients With Platinum-Resistant Ovarian Cancer That Has High Levels of Cyclin E1 Protein

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.

Colorectal cancer metastatic

Recruiting

Comparing irinotecan plus cetuximab with trifluridine and tipiracil plus bevacizumab for patients with metastatic colorectal cancer as third line treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale

Acute lymphocytic leukaemia recurrent+5

Recruiting

A study testing AZD3632 alone or with other anticancer drugs in adults with acute leukemia or myelodysplastic syndromes with HOX gene overexpression

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AZD3632
  • Sponsor:AstraZeneca AB

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.